tbuckley/cabot-search huggingface dataset:
Inhibition of Dimethylnitrosamine-Induced Strand Breaks in Liver DNA and Liver Cell Necrosis by Diethyldithiocarbamate 2
Authors: s. E. Abanobi, J. A. Popp, S. K. Chang, G. W. Harrington, P. D. Lotlikar, D. Hadjiolov, M. Levitt, S. Rajalakshmi, D. S. R. Sarma
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Inhibition of Dimethylnitrosamine-Induced Strand Breaks in Liver DNA and Liver Cell Necrosis by Diethyldithiocarbamate Get access s. E. Abanobi, s. E. Abanobi Search for other works by this author on: Oxford Academic PubMed Google Scholar J. A. Popp, J. A. Popp Search for other works by this author on: Oxford Academic PubMed Google Scholar S. K. Chang, S. K. Chang Search for other works by this author on: Oxford Academic PubMed Google Scholar G. W. Harrington, G. W. Harrington Search for other works by this author on: Oxford Academic PubMed Google Scholar P. D. Lotlikar, P. D. Lotlikar Search for other works by this author on: Oxford Academic PubMed Google Scholar D. Hadjiolov, D. Hadjiolov Search for other works by this author on: Oxford Academic PubMed Google Scholar M. Levitt, M. Levitt Search for other works by this author on: Oxford Academic PubMed Google Scholar S. Rajalakshmi, S. Rajalakshmi Search for other works by this author on: Oxford Academic PubMed Google Scholar D. S. R. Sarma D. S. R. Sarma Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 2, February 1977, Pages 263–271, https://doi.org/10.1093/jnci/58.2.263 Published: 01 February 1977 Article history Received: 03 August 1975 Revision received: 03 June 1976 Accepted: 14 June 1976 Published: 01 February 1977
319P The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN): A retrospective analysis
Authors: T. Wakasugi, T. Enokida, A. Nakanome, T. Yamazaki, S. Okano, M. Tahara
Journal: Annals of Oncology (2015)
Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism
Authors: Nikita Joshi, Anna K. Kopec, Jessica L. Ray, Holly Cline-Fedewa, Atta Nawabi, Timothy Schmitt, Rance Nault, Timothy R. Zacharewski, Cheryl E. Rockwell, Matthew J. Flick, James P. Luyendyk
Journal: Blood (2016)
Acute Infusional Reactions to Chemotherapy in an Outpatient Unit: Experience from 21,394 Treatment Cycles in Brazil
Authors: P.H. Isaacsson, M.C. Teixeira, M. Scaranti, A.R. Matutino, M.V. Negrao, N. Fraile, K.T. Souza, C.T. Yen, G. Pinheiro, P.M. Hoff, None G.C.
Journal: Annals of Oncology (2014)
Abstract 8694: Phosphodiesterase 3 Inhibitor Prevents Thrombotic Diseases Without Affecting Hemostatic Function
Authors: Hideo Yoshida, Yusuke Sasaki, Shinsuke Itoh, Shoichi Kondo, Sohei Tanabe, Yoshihiro Inoue
Journal: Circulation (2011)

Introduction: Conventional anti-platelet therapy is associated with increased risk of bleeding. Recently, the results of the second Cilostazol Stroke Prevention Study (CSPS 2) showed similar efficacy but fewer hemorrhagic events with the phosphodiesterase (PDE)3 inhibitor cilostazol vs. aspirin. Hypothesis: We hypothesized that PDE3 inhibition reduces thrombus formation without affecting hemostasis, and leads to beneficial effects in experimental cerebral infarction and peripheral artery disease (PAD) models Methods: We used a cilostazol analog, K-134, as a more potent and selective PDE3 inhibitor. To evaluate the anti-thrombus activity of K-134, we measured mortality rate in a pulmonary embolism model established by collagen infusion into mice via the tail vein 10 min after oral administration of K-134. We also studied its influence on tail vein bleeding times. To investigate whether K-134 can ameliorate other thrombotic diseases, we established a rat cerebral infarction model by photochemically induced thrombosis-mediated occlusion of middle cerebral arteries and a PAD model by laurate injection-mediated peripheral arterial injury. Pathological signs in the areas of necrosis in the hind legs in the PAD model were classified as Grade 0 to 5. Results: K-134 decreased mortality in the mouse pulmonary embolism model when orally administered at 3, 10, and 30 mg/kg ( n = 29-30, P &lt; 0.01 vs. control, ED50 = 2.1 mg/kg) but did not prolong bleeding time even at 100 mg/kg compared to control ( n = 30, 98 ± 6 vs. 84 ± 7 s., not significant). In contrast, warfarin prolonged bleeding time ( n = 29-30, 139 ± 7 vs. 84 ± 7 s., P &lt; 0.01). Preoperative administration of K-134 at 30 mg/kg reduced brain infarct size compared to control in the rat cerebral infarction model ( n = 12, 87.5 ± 5.6 vs. 126.8 ± 7.5 mm 3 , P &lt; 0.01). Furthermore, 30 mg/kg K-134 inhibited the progression of lesions compared with controls in the PAD model ( n = 12-15, mean grade of pathological sign: 2.3 ± 0.2 vs. 3.5 ± 0.3, P &lt; 0.05). Conclusion: PDE3 inhibition is an attractive approach for the secondary prevention of cerebral infarction and treatment of peripheral arterial disease.
Impact of body mass index on biochemical outcomes after definitive therapy for localized prostate cancer
Authors: A. Mahadevan, K. Stephans, A. M. Reuther, S. T. Chao, E. A. Klein
Journal: Journal of Clinical Oncology (2005)

4658 Background: We reviewed the impact of body mass index (BMI) on biochemical relapse-free survival (bRFS) after external beam radiation therapy (EBRT), brachytherapy (B), and radical prostatectomy (RP) for clinical T1-T3 prostate cancer in a large single institution cohort. Methods: The study included 1036 treated (1992–1999) patients from our prospectively managed database. No cases received neoadjuvant or adjuvant hormonal therapy. Biochemical failure (BF) was defined as a PSA >0.2 or two consecutive PSAs of 0.2 after RP and by ASTRO definition for RT (EBRT and B). Kaplan-Meier and Cox-proportional hazards analyses were used to determine if BMI predicted BF or adverse pathology. Results: The 9-year bRFS for normal (n=281), overweight (n=524), and obese (n=231, OB) was 68%, 72%, 63%, respectively (p=0.0072). The median PSA follow-up was 76 months (range: 24 to 150). Obesity (BMI ≥ 30) was not associated with higher bGS. OB adversely impacted bRFS on univariate analysis (p=0.0079), but after controlling for all preop clinical variables (T-stage, iPSA, bGS), OB did not significantly predict BF. Amongst 517 RP patients, OB was significantly associated with positive margins (PM) (p=0.0014), seminal vesicle invasion (SVI) (p=0.0625), and extracapsular extension (ECE) (p=0.0702), but not with surgical Gleason score (sGS). The 9-year bRFS rate for normal, overweight, and OB was 73%, 73%, 66%, respectively (p=0.0323). In the univariate, BMI was a predictor of bRFS (p=0.0358). In the multivariate, BMI was a significant risk factor of bRFS (p=0.0069) after controlling for T-stage (p<0.0001), iPSA (p=0.0014), bGS (p<0.0001). However, after controlling for PM, SVI, ECE, sGS, BMI was not significant for BF. Of the patients who had RT (n=519), EBRT (n=392), or B (n=127), BMI was not a predictor of BF. Conclusions: OB men do not have an inherently more aggressive form of prostate cancer in this dataset. Although BMI ≥ 30 adversely impacted bRFS on univariate analysis, it was not associated with increased risk of bRFS after controlling for clinicopathologic characteristics. RP in OB patients was significantly associated with adverse path features, perhaps related to technical difficulties. No significant financial relationships to disclose.
Expression of an Antigen Associated With Acute Lymphoblastic Leukemia in Human Leukemia-Lymphoma Cell Lines 2
Authors: Jun Minowada, George Janossy, Melvyn F. Greaves, Teruhiko Tsubota, B. I. Sahai Srivastava, Shigeru Morikawa, Eiji Tatsumi
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Expression of an Antigen Associated With Acute Lymphoblastic Leukemia in Human Leukemia-Lymphoma Cell Lines Get access Jun Minowada, Jun Minowada Search for other works by this author on: Oxford Academic PubMed Google Scholar George Janossy, George Janossy Search for other works by this author on: Oxford Academic PubMed Google Scholar Melvyn F. Greaves, Melvyn F. Greaves Search for other works by this author on: Oxford Academic PubMed Google Scholar Teruhiko Tsubota, Teruhiko Tsubota Search for other works by this author on: Oxford Academic PubMed Google Scholar B. I. Sahai Srivastava, B. I. Sahai Srivastava Search for other works by this author on: Oxford Academic PubMed Google Scholar Shigeru Morikawa, Shigeru Morikawa Search for other works by this author on: Oxford Academic PubMed Google Scholar Eiji Tatsumi Eiji Tatsumi Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 6, June 1978, Pages 1269–1277, https://doi.org/10.1093/jnci/60.6.1269 Published: 01 June 1978 Article history Received: 14 September 1977 Accepted: 05 December 1977 Published: 01 June 1978
The response of atrioventricular junctional tissue to temperature.
Authors: Kenzo Hirao, Tadashi Sato, Kenichiro Otomo, Naoto Yamamoto, Hiroko Nawara, Nobuo Doshida, Fumio Suzuki, Tokuhiro Kawara, Kazumasa Hiejima, Michio Tanaka
Journal: Circulation (1994)

To determine the optimal temperature for catheter heat mapping without damaging cardiac tissue, we studied the electrophysiologic and histologic responses of the atrioventricular (AV) conduction system exposed to a specific range of temperatures. In 18 closed-chest dogs, an electrode catheter with a thermistor, tip was positioned transvenously at the AV junction. Radiofrequency current (RFC) was applied in incremental temperature steps until transient 2nd-degree AV block was induced. Catheter tip temperature (CTT) was measured at each step. RFC was immediately discontinued when AV block occurred. AV conduction was evaluated before and 4 weeks after the procedure. Acute transient 2nd-degree AV block was induced in 45 applications, during which the average CTT was 48.7±2.7°C. In another 40 applications in which 2nd degree AV block was not induced, the average CTT was significantly lower [46.3±2.5°C] (p<0.001). Eleven of 16 dogs showed acute 2nd-degree AV block, but had normal AV conduction at 4 weeks (Group A). In the other 5 dogs, 1st-degree AV block was seen at 4 weeks (Group B). The lowest CTTs in Groups A and B were 45 and 49°C, respectively. Histologic findings in 2 dogs from Group A revealed that 10-15% (by area) of the AV node was fibrotic. These findings suggest that the induction of fully reversible AV block can be achieved by titration of RFC, during the application of RFC to the AV junction. In conclusion, RF energy was used to produce a tip temperature of between 45°C and 49°C, which induced reversible and significant interruption of conduction of in tissue in the AV junction, and presumably also in target sites in clinical RF ablation.
Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET
Authors: Tony Reid, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Bryan Oronsky, Gary Fanger, Meaghan Stirn, Scott Caroen, Christopher Parker, Jan Scicinski
Journal: Cancer Research (2016)

Abstract Background: The development of resistance to chemotherapies in cancer leads to disease progression resulting in impaired survival. Resensitization to these previously effective but now failed therapies could lead to improvements in patient survival and response. RRx-001, a novel dinitroazetidine ROS-mediated epigenetic modulator that has demonstrated activity against DNMTs and HDACs may resensitize colorectal cancer patients to previously effective irinotecan therapies resulting in improvements in survival. Methods: The ROCKET study is a two stage trial that investigates RRx-001-mediated resensitization to irinotecan therapies. Patients with metastatic colorectal cancer who previously responded, then progressed on irinotecan-based therapies, with or without bevacizumab, cetuximab or panitumumab and an ECOG PS 0-1 are randomized in Stage 1 to receive RRx-001 1xweek or regorafenib until progression or unacceptable toxicity. Patients then advance to Stage 2 to receive irinotecan-based therapies. Target accrual is approx. 190 patients and the primary endpoint is overall survival with secondary endpoints to investigate resensitization. Recruitment is ongoing. Study Status and Results: To date, 28 patients have been randomized with 20 entering the resensitization stage of the study. 13 post RRx-001 patients entered the second stage of the study showing an improving patient survival, marked decreases in CEA and radiological responses. In contrast, the 7 regorafenib patients eligible for stage 2 were too systemically unwell to proceed to subsequent treatment. Conclusions: Early results suggest that RRx-001, a systemically non-toxic epigenetic agent, may resensitize colorectal cancer patients to irinotecan-based therapies. These interesting early results appear to be generalized and may translate to increased overall survival, adding an additional regimen after disease progression. The trial is continuing. Citation Format: Tony Reid, George Fisher, Corey Carter, Cheryl Cho-Phan, Pamela Kunz, Bryan Oronsky, Gary Fanger, Meaghan Stirn, Scott Caroen, Christopher Parker, Jan Scicinski. RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET. [abstract]. In: Proceedings of the AACR Special Conference on Chromatin and Epigenetics in Cancer; Sep 24-27, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2016;76(2 Suppl):Abstract nr B26.
Short biceps femoris fascicles and eccentric knee flexor weakness increase the risk of hamstring injury in elite football (soccer): a prospective cohort study
Authors: Ryan G Timmins, Matthew N Bourne, Anthony J Shield, Morgan D Williams, Christian Lorenzen, David A Opar
Journal: British Journal of Sports Medicine (2015)

To investigate the role of eccentric knee flexor strength, between-limb imbalance and biceps femoris long head (BFlh) fascicle length on the risk of future hamstring strain injury (HSI).Elite soccer players (n=152) from eight different teams participated. Eccentric knee flexor strength during the Nordic hamstring exercise and BFlh fascicle length were assessed at the beginning of preseason. The occurrences of HSIs following this were recorded by the team medical staff. Relative risk (RR) was determined for univariate data, and logistic regression was employed for multivariate data.Twenty seven new HSIs were reported. Eccentric knee flexor strength below 337 N (RR=4.4; 95% CI 1.1 to 17.5) and possessing BFlh fascicles shorter than 10.56 cm (RR=4.1; 95% CI 1.9 to 8.7) significantly increased the risk of a HSI. Multivariate logistic regression revealed significant effects when combinations of age, history of HSI, eccentric knee flexor strength and BFlh fascicle length were explored. From these analyses the likelihood of a future HSI in older athletes or those with a HSI history was reduced if high levels of eccentric knee flexor strength and longer BFlh fascicles were present.The presence of short BFlh fascicles and low levels of eccentric knee flexor strength in elite soccer players increases the risk of future HSI. The greater risk of a future HSI in older players or those with a previous HSI is reduced when they have longer BFlh fascicles and high levels of eccentric strength.
Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia
Authors: Carmen L. Wilson, Wassim Chemaitilly, Kendra E. Jones, Sue C. Kaste, Deo Kumar Srivastava, Rohit P. Ojha, Yutaka Yasui, Ching-Hon Pui, Leslie L. Robison, Melissa M. Hudson, Kirsten K. Ness
Journal: Journal of Clinical Oncology (2016)

Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes potentially modifiable by altering health behaviors and/or treating endocrine abnormalities. We evaluated associations between lifestyle and hormonal deficits with risk of low BMD and frailty among survivors of ALL.
Notch Alters Sumoylation To Govern GFI1 Protein Stability and Support Its Transcriptional Repression Function
Authors: Jason Singer, Daniel Andrade, Diana Bareyan, David McClellan, Helena Lucente, Matthew Velinder, Mahesh Chandrasekharan, Emily Theisen, Fang Liu, Sunil Sharma, Luke Maese, Michael E Engel
Journal: Blood (2013)
Incidence and Pattern of Second Neoplasms in Patients Diagnosed with Invasive Transitional Carcinoma of the Urinary Tract
Authors: A.C. Vethencourt, A. Gómez de Liaño Lista, G. Sancho Pardo, J. Palou, D. Páez, L.P. Del Carpio, C. Arqueros, N. Dueñas, A.C. Virgili, A. Barnadas, P. Maroto
Journal: Annals of Oncology (2014)
Chronic Ursodeoxycholic Acid- and Chenodeoxycholic Acid-Feeding-Induced Changes of Colon Mucosal Cell Proliferation in Rats&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: U A Simanowski, H K Seitz, P Czygan, M Hörner, R Waldherr, E Weber, B Kommerell
Journal: JNCI Journal of the National Cancer Institute (1987)

Hyperproliferation has been suggested to play a major role in bile acid-dependent colorectal tumor promotion. Effects of chronic feeding of chenodeoxycholic acid (CDC) and ursodeoxycholic acid (UDC) were tested on cell proliferation in the colon of male noninbred Wistar rats. By use of a dynamic method measuring actual rates of cell production, proliferation was modulated by both bile acids only in the proximal part of the colon. UDC feeding produced mild hyperproliferation of basal crypt cells (cell position 5-8: 7.6 +/- 2.0 vs. 3.5 +/- 1.3 cells/1,000 cells/hr--P less than .05; cell position 9-12: 18.1 +/- 10.7 vs. 10.3 +/- 2.9--P less than .05; cell position 13-16: 18.1 +/- 8.9 vs. 9.1 +/- 2.3--P less than .05). This finding reflected a characteristic compensatory response to superficial cell damage. However, CDC application did not effect cell regeneration in this crypt area but led to a striking drop of cell renewal in higher crypt cell positions (positions greater than or equal to 17), where no proliferation was detectable. These data suggest that CDC exerts its tumor-promoting effect by other means than hyperproliferation.
Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Authors: G. Sonpavde, M. M. Khan, S. P. Lerner, R. S. Svatek, E. C. Skinner, P. I. Karakiewicz, W. Kassouf, C. P. Dinney, Y. Fradet, S. F. Shariat
Journal: Journal of Clinical Oncology (2010)

4576 Background: The conventional primary end point in trials of perioperative systemic therapy for muscle-invasive bladder is 5-year overall survival (OS). Disease-free survival (DFS) at 2-3 years may be an intermediate end point that correlates with 5-year OS. Methods: A multicenter (10 sites) American-European database of patients with bladder cancer that underwent radical cystectomy (RC) with negative margins from October 1971 to April 2008 was analyzed. The median follow-up was 72 months and eligible patients had muscle-invasive pathological (p)T2-T4aN0 or node-positive disease. Of a total of 2724 patients, 844 had received adjuvant chemotherapy; 997 had pT2 and 1727 patients had ≥pT3 (including node positive) disease. Recurrence and survival were analyzed to investigate the individual levels of association between DFS at 2 years (DFS2) or 3 years (DFS3) with OS at 5 years (OS5) using Cox proportional hazards modeling. The kappa statistic was calculated to determine agreement above that expected by chance. Results: The overall DFS2/DFS3 was 0.63/0.57; for pT2= 0.77/0.72 and for ≥pT3=0.54/0.48. Of all recurrences, 71.2% occurred in 2 years, and 83.4% in 3 years. The 5-year OS was 0.47; for pT2= 0.61 and for ≥pT3=0.39. The overall agreement between DFS2 and OS5 was 79%, and between DFS3 and OS5 was 81%. Agreements were similar when analyzed by stage (pT2= 82%, ≥pT3= 80%) in patients that either received (81%) or did not receive (78%) adjuvant chemotherapy, and for time of RC up to 1990 (80%) or after 1990 (79%). The kappa statistic was 0.57 (95% CI, 0.53, 0.60) for DFS2/OS5 and 0.61 (95% CI, 0.58, 0.64) for DFS3/OS5, indicating moderate agreement. The hazard ratio for progression as a time-dependent variable was 12.7 (95% CI, 11.60, 13.90) indicating a strong relationship between progression and survival. Conclusions: Both 2 and 3-year DFS correlate with and are potential intermediate surrogates for 5-year OS in patients with muscle-invasive bladder cancer undergoing RC with/without adjuvant chemotherapy. These data require validation and may also be applicable to neoadjuvant therapy and assist in accelerating the development of perioperative systemic therapy. No significant financial relationships to disclose.
Antidiuretic Action of Collecting Duct (Pro)Renin Receptor Downstream of Vasopressin and PGE2 Receptor EP4
Authors: Fei Wang, Xiaohan Lu, Kexin Peng, Hui Fang, Li Zhou, Jiahui Su, Adam Nau, Kevin T. Yang, Atsuhiro Ichihara, Aihua Lu, Shu-Feng Zhou, Tianxin Yang
Journal: Journal of the American Society of Nephrology (2016)

Within the kidney, the (pro)renin receptor (PRR) is predominantly expressed in the collecting duct (CD), particularly in intercalated cells, and it is regulated by the PGE 2 receptor EP 4 . Notably, EP 4 also controls urinary concentration through regulation of aquaporin 2 (AQP2). Here, we tested the hypothesis that sequential activation of EP 4 and PRR determines AQP2 expression in the CD, thus mediating the antidiuretic action of vasopressin (AVP). Water deprivation (WD) elevated renal PRR expression and urinary soluble PRR excretion in rats. Intrarenal infusion of a PRR decoy peptide, PRO20, or an EP 4 antagonist partially prevented the decrease in urine volume and the increase in urine osmolality and AQP2 expression induced by 48-hour WD. In primary cultures of rat inner medullary CD cells, AQP2 expression induced by AVP treatment for 24 hours depended on sequential activation of the EP 4 receptor and PRR. Additionally, mice lacking PRR in the CD exhibited increased urine volume and decreased urine osmolality under basal conditions and impaired urine concentrating capability accompanied by severe volume loss and a dangerous level of plasma hyperosmolality after WD. Together, these results suggest a previously undescribed linear AVP/PGE 2 /EP 4 /PRR pathway in the CD for regulation of AQP2 expression and urine concentrating capability.